Clipos™ Gilteritinib (ASP2215) Encapsulated Liposomes
Specifications
Description
|
Gilteritinib (ASP2215) is a small-molecule inhibitor of FLT3/AXL with IC50 values of 0.29 nM and 0.73 nM for FLT3 and AXL, respectively. Gilteritinib (ASP2215) is a highly selective FLT3 inhibitor that demonstrates activity against both FLT3-ITD and FLT3-TKD mutation subtypes and selectively inhibits FLT3 at concentrations roughly 800-fold lower than those required to inhibit c-Kit (230 nM). This product is a pre-formulated liposomal version of Gilteritinib (ASP2215) which is supplied ready to use in vitro or in vivo. The liposomes are PEGylated for optimal in vivo performance; the lipid composition of the liposomes is the same as Doxil. For preclinical research use only. |
Lipid composition
|
HSPC/Chol/DSPE-mPEG2000 (56.2/38.5/5.3 molar ratio) |
Liposome Size
|
70-120 nm |
Lipid Molar Concentration
|
26.4 mM |
Encapsulated Drug
|
Gilteritinib |
Drug concentration
|
2.5 mg/mL |
Inside Buffer
|
250 mM ammonium sulfate, pH 5.5 |
Outside Buffer
|
DPBS (1X), pH 7.4 |
Storage
|
2 °C to 8 °C (do not freeze), stored under nitrogen |
Shelf-life
|
At least 3 months |
CAS No.
|
1254053-43-4 |
Related Products